890 Shares in Inari Medical, Inc. (NASDAQ:NARI) Bought by R Squared Ltd

R Squared Ltd purchased a new stake in shares of Inari Medical, Inc. (NASDAQ:NARI) during the fourth quarter, HoldingsChannel reports. The fund purchased 890 shares of the company’s stock, valued at approximately $45,000.

Several other institutional investors have also bought and sold shares of NARI. SG Americas Securities LLC purchased a new stake in shares of Inari Medical during the 3rd quarter valued at about $625,000. Handelsbanken Fonder AB increased its stake in Inari Medical by 22.1% during the third quarter. Handelsbanken Fonder AB now owns 16,000 shares of the company’s stock worth $660,000 after acquiring an additional 2,900 shares during the last quarter. GAMMA Investing LLC increased its stake in Inari Medical by 67.2% during the third quarter. GAMMA Investing LLC now owns 1,177 shares of the company’s stock worth $49,000 after acquiring an additional 473 shares during the last quarter. Everence Capital Management Inc. purchased a new stake in Inari Medical during the third quarter valued at approximately $315,000. Finally, Values First Advisors Inc. purchased a new position in shares of Inari Medical in the 3rd quarter worth approximately $128,000. Institutional investors own 90.98% of the company’s stock.

Inari Medical Trading Down 0.0 %

NARI opened at $79.67 on Monday. The company has a market capitalization of $4.66 billion, a price-to-earnings ratio of -59.01 and a beta of 0.97. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $79.76. The business’s fifty day simple moving average is $63.35 and its 200-day simple moving average is $52.53.

Insider Buying and Selling

In other news, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $55.29, for a total value of $165,870.00. Following the completion of the transaction, the chief executive officer now directly owns 439,310 shares of the company’s stock, valued at approximately $24,289,449.90. The trade was a 0.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William Hoffman sold 200,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $60.47, for a total value of $12,094,000.00. Following the sale, the director now directly owns 238,987 shares in the company, valued at approximately $14,451,543.89. The trade was a 45.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 323,000 shares of company stock valued at $18,669,070 over the last three months. 10.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on NARI shares. Piper Sandler increased their price target on Inari Medical from $52.00 to $80.00 and gave the company a “neutral” rating in a report on Tuesday, January 7th. Baird R W downgraded shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 7th. Oppenheimer initiated coverage on shares of Inari Medical in a research note on Tuesday, December 17th. They set an “outperform” rating and a $75.00 price target for the company. Canaccord Genuity Group reissued a “hold” rating and issued a $80.00 price objective (up from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $80.00 price objective (down previously from $81.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Twelve equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $68.00.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.